RT Journal Article
SR Electronic
T1 Quantitative Flow Ratio to Predict Non-Target-Vessel Events Prior to Planned Staged PCI in ACS Patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.07.24.23292979
DO 10.1101/2023.07.24.23292979
A1 Bär, Sarah
A1 Kavaliauskaite, Raminta
A1 Otsuka, Tatsuhiko
A1 Ueki, Yasushi
A1 Häner, Jonas
A1 Lanz, Jonas
A1 Fürholz, Monika
A1 Praz, Fabien
A1 Hunziker, Lukas
A1 Siontis, George CM
A1 Pilgrim, Thomas
A1 Stortecky, Stefan
A1 Losdat, Sylvain
A1 Windecker, Stephan
A1 Räber, Lorenz
YR 2023
UL http://medrxiv.org/content/early/2023/07/27/2023.07.24.23292979.abstract
AB Background The optimal timepoint of staged percutaneous coronary intervention (sPCI) among patients with acute coronary syndrome (ACS) and multivessel disease (MVD) remains a matter of debate. Quantitative Flow Ratio (QFR) is a novel non-invasive method to assess the hemodynamic significance of coronary stenoses. We aimed to investigate whether QFR could optimize the timing of sPCI of non-target-vessels (non-TV) among ACS patients with MVD.Methods For this cohort study, ACS patients discharged from Bern University Hospital, Switzerland, were eligible if non-TV sPCI was scheduled within 6 months after index PCI. The primary endpoint was non-TV myocardial infarction (MI) and urgent unplanned non-TV PCI before planned sPCI. The association between lowest QFR per patient measured in non-TV (from index angiogram) and the primary endpoint was assessed using a multivariable adjusted Cox proportional hazards regression with QFR included as linear and penalized spline (non-linear) terms.Results QFR was measured in 1093/1432 ACS patients scheduled to undergo non-TV sPCI. Median time to sPCI was 28 days. The primary endpoint occurred in 5% of the patients. In multivariable analysis (1018 patients), there was no independent association between non-TV QFR and the primary endpoint (HR 0.87, 95% CI 0.69-1.05 [per 0.1 increase], p=0.125; non-linear p=0.648).Conclusions In ACS patients scheduled to undergo sPCI at a median of 4 weeks after index PCI, QFR did not emerge as independent predictor of non-TV events prior to planned sPCI. Thus, this study does not provide conceptual evidence, that QFR is helpful to optimize the timing of sPCI.Clinical Trial Registration ClinicalTrials.gov:NCT02241291Clinical Perspective What is new? This was the first study to investigate the association between non-target-vessel (non-TV) Quantitative Flow Ratio (QFR) and non-TV events occurring prior to planned staged percutaneous coronary intervention (PCI) among acute coronary syndrome (ACS) patients with multivessel disease, to derive first conceptual knowledge, whether QFR could be helpful to optimize the timing of staged PCI.Among 1093 ACS patients and 1262 non-TV scheduled to undergo out-of-hospital staged PCI within a median of 28 days from index PCI, QFR did not emerge as an independent predictor of non-TV events occurring prior to planned staged PCI.What are the clinical implications? Among ACS patients in whom, according to the operator’s judgment, it is feasible to perform out-of-hospital staged PCI within a median of 1 month from index PCI, this study does not provide conceptual evidence, that QFR could be helpful to optimize the timing of staged PCI (i.e. to schedule staged PCI earlier in case of lower QFR).Grapical AbstractStudy design (left) and primary endpoint results (right). For non-linear QFR, hazard ratios were calculated using the reference hazard corresponding to QFR=0.80 (grey dashed line) from a Cox proportional hazards model with penalized splines. ACS = acute coronary syndrome, CI = confidence interval, DS% = diameter stenosis, HR = hazard ratio, non-TV-MI = non-target-vessel myocardial infarction, non-TV-PCI = non-target-vessel percutaneous coronary intervention, PCI = percutaneous coronary intervention, QFR = Quantitative Flow Ratio, 1°EP = primary endpoint.Competing Interest StatementDr. Baer, reports research grants to the institution from Medis Medical Imaging Systems, Abbott, Bangerter-Rhyner Stiftung, and a personal research grant from the Swiss National Science Foundation, outside the submitted work. Dr. Ueki reports personal fees from Infraredex, outside the submitted work. Dr. Losdat is employed by CTU Bern, University of Bern, which has a staff policy of not accepting honoraria or consultancy fees. However, CTU Bern is involved in design, conduct, or analysis of clinical studies funded by not-for-profit and for-profit organizations. In particular, pharmaceutical and medical device companies provide direct funding to some of these studies. For an up-to-date list of CTU Bern's conflicts of interest: http://www.ctu.unibe.ch/research/declaration_of_interest/index_eng.html. Prof. Praz has received travel expenses from Abbott Vascular, Edwards Lifesciences, and Polares Medical. Dr. Haener has received a travel grant from Bayer. Prof. Stortecky reports research grants to the institution from Edwards Lifesciences, Medtronic, Abbott Vascular, and Boston Scientific; speaker fees from Boston Scientific; consulting fees from BTG and Teleflex, outside the submitted work. Prof. Pilgrim reports research grants to the institution from Boston Scientific, Biotronik, and Edwards Lifesciences; speaker fees from Boston Scientific and Biotronik; Consultancy for HighLife SAS; proctoring for Boston Scientific and Medtronic. Stephan Windecker reports research, travel or educational grants to the institution without personal remuneration from Abbott, Abiomed, Amgen, Astra Zeneca, Bayer, Braun, Biotronik, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardinal Health, CardioValve, Cordis Medical, Corflow Therapeutics, CSL Behring, Daiichi Sankyo, Edwards Lifesciences, Farapulse Inc. Fumedica, Guerbet, Idorsia, Inari Medical, InfraRedx, Janssen-Cilag, Johnson & Johnson, Medalliance, Medicure, Medtronic, Merck Sharp & Dohm, Miracor Medical, Novartis, Novo Nordisk, Organon, OrPha Suisse, Pharming Tech. Pfizer, Polares, Regeneron, Sanofi-Aventis, Servier, Sinomed, Terumo, Vifor, V-Wave. Stephan Windecker served as advisory board member and/or member of the steering/executive group of trials funded by Abbott, Abiomed, Amgen, Astra Zeneca, Bayer, Boston Scientific, Biotronik, Bristol Myers Squibb, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Recardio, Sinomed, Terumo, and V-Wave with payments to the institution but no personal payments. He is also member of the steering/executive committee group of several investigator-initiated trials that receive funding by industry without impact on his personal remuneration. Prof. Raeber reports research grants to the institution from Abbott Vascular, Biotronik, Boston Scientific, Heartflow, Sanofi, Regeneron, Medis Medical Imaging Systems, Bangerter-Rhyner Stiftung; speaker or consultation fees by Abbott Vascular, Amgen, AstraZeneca, Canon, Novo Nordisk, Medtronic, Occlutech, and Sanofi, outside the submitted work. All other authors report no conflicts of interest.Funding StatementnoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of the Canton of Bern, Switzerland, (Kantonale Ethikkommission, 3010 Bern, Switzerland) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data that support the findings of this study will be made available upon reasonable request from the corresponding author.Non-standard Abbreviations and AcronymsMVDmultivessel diseaseNon-TVnon-target vesselQFRQuantitative Flow Ratio3D-QCA3D-Quantitative Coronary Angiography